

Comparing wait times for an Alzheimer's treatment in Canada and other G7 countries

Description

[vc_row][vc_column][vc_column_text]Soeren Mattke, MD DSc, University of Southern California, Los Angeles, USA

Mo Wang, MS, University of Southern California, Los Angeles, USA

The emerging disease-modifying Alzheimer's treatments present a health system challenge because of the combination of a large prevalent patient pool and a complex diagnostic process. Analyses of system preparedness have projected Canada to have the longest and most protracted wait times for access among G7 countries. This policy analysis used comparative health system data and 17 semi-structured interviews with experts in Canada. The authors conclude that Canada faces a unique challenge to make a disease-modifying Alzheimer's treatment accessible because of limited capacity for memory care.

PREVIEW: January 27, 2022 | PUBLISHED: January 31, 2022[/vc_column_text][vc_column][vc_row][vc_row][vc_column][vc_btn title="Get Article" link="url:https%3A%2F%2Fwww.canadianhealthpolicy.com%2Fproduct%2Fwhy-would-canada-have-the-longest-wait-times-for-an-alzheimers-treatment-among-the-g7-countries%2F|title:Get%20Article|target:_blank"][/vc_column][vc_row]